Evidence map›Paper›PMID 39531158›Full record

ArticleLa Radiologia medica2025

Metastasis-directed ablation of hepatocellular carcinoma with pulmonary oligometastases: a long-term multicenter study.

Qunfang Zhou, Ruixia Li, Songsong Wu, Yanyang Zhang, Wei Wang, Kangshun Zhu, Murong Wang, Zhimei Huang, Feng Duan

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qunfang ZhouDepartment of Interventional Radiology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, China.
Ruixia LiDepartment of Liver Surgery, The First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Er Road, Guangzhou, Guangdong Province, China.
Songsong WuDepartment of Ultrasonography, Fujian Provincial Hospital, East Road 134, Fuzhou, Fujian Province, China.
Yanyang ZhangDepartment of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-Sen University, Tianhe Road 600, Guangzhou, Guangdong Province, China.
Wei WangDepartment of General Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, China.
Kangshun ZhuDepartment of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, 250 Changgang East Road, Guangzhou, Guangdong Province, China.
Murong WangDepartment of Minimally Invasive Interventional Radiology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, Guangdong Province, China.
Zhimei HuangDepartment of Minimally Invasive Interventional Radiology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, Guangdong Province, China. huangzhm@sysucc.org.cn.
Feng DuanDepartment of Interventional Radiology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, China. duanfeng@vip.sina.com.

Funding

National Natural Science Foundation of China 82172037Natural Science Foundation of Guangdong Province 2023A1515010499
6 · The paper itself

Abstract

purposeAblation is a promising approach for eliminating intrathoracic metastases. We compared the effectiveness of a combination of metastasis-directed ablation and systemic therapy with that of systemic therapy alone for patients with hepatocellular carcinoma (HCC) having pulmonary oligometastases. MATERIALS AND

methodsWe analyzed 679 patients with HCC and pulmonary oligometastases from seven tertiary hospitals. A total of 372 patients received systemic therapy (System group), whereas 307 patients received the combination therapy of pulmonary oligometastases ablation and systemic therapy (Ablation + System group).

resultsThe median progression-free survival (PFS) was 9.7 ± 0.6 and 11.5 ± 0.6 months in the System and Ablation + System groups, respectively. The Ablation + System group exhibited significantly better PFS (hazard ratio [HR], 0.71; 95% confidence interval [CI] 0.60-0.85; P < 0.001) and overall survival (OS) (HR, 0.65; 95% CI 0.52-0.81; P < 0.001) than the System group. The subgroup analysis revealed that OS (HR, 0.91; 95% CI 0.65-1.28; P = 0.590) and PFS (HR, 0.81; 95% CI 0.62-1.05; P = 0.100) did not differ between tyrosine kinase inhibitor (TKI) and TKI plus programmed cell death protein-1 (PD-1) inhibitor therapies in the Ablation + system group. In addition, PFS (HR, 0.53; 95% CI 0.38-0.74; P < 0.001) and OS (HR, 0.66; 95% CI 52-0.84; P < 0.001) showed obviously different for intrahepatic tumors with partial response (PR) status.

conclusionThe application of a combination of ablation of pulmonary oligometastases and systemic therapy resulted in longer PFS and OS than systemic therapy alone.

Indexed as

Ablation TechniquesCarcinoma, HepatocellularCatheter AblationLiver NeoplasmsLung NeoplasmsAdultAgedCombined Modality TherapyFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAblationHepatocellular carcinomaMulticenter studyPulmonary oligometastasesSystem therapy

Identifiers

PMID39531158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.